Physiological Basis for Xenotransplantation from Genetically-Modified Pigs to Humans: A Review.

Genetically-modified pigs Xenotransplantation

Journal

Physiological reviews
ISSN: 1522-1210
Titre abrégé: Physiol Rev
Pays: United States
ID NLM: 0231714

Informations de publication

Date de publication:
22 Mar 2024
Historique:
medline: 22 3 2024
pubmed: 22 3 2024
entrez: 22 3 2024
Statut: aheadofprint

Résumé

The collective efforts of scientists over multiple decades have led to advancements in molecular and cellular biology-based technologies including genetic engineering and animal cloning, that are now being harnessed to enhance the suitability of pig organs for xenotransplantation into humans. Using organs sourced from pigs with multiple gene deletions and human transgene insertions, investigators have overcome formidable immunological and physiological barriers in pig-to-non-human primate (NHP) xenotransplantation and achieved prolonged pig xenograft survival. These studies informed the design of Revivicor's (Revivicor Inc, Blacksburg, VA) genetically engineered pig with 10 genetic modifications (10 GE) (including the inactivation of 4 endogenous porcine genes and insertion of 6 human transgenes) whose hearts and kidneys have now been studied in preclinical human xenotransplantation models using brain-dead recipients. Additionally, the first two clinical cases of pig-to-human heart xenotransplantation were recently performed using hearts from this 10 GE pig at the University of Maryland. While this review focuses on xenotransplantation of hearts and kidneys, multiple organs, tissues, and cell-types from genetically engineered pigs will provide much-needed therapeutic interventions in the future.

Identifiants

pubmed: 38517040
doi: 10.1152/physrev.00041.2023
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Leigh Peterson (L)

Product Development and Xenotransplantation, United Therapeutics, Durham, NC, United States.

Magdi Yacoub (M)

National Heart and Lung Institute, Imperial College London, London, United Kingdom.

David Ayares (D)

Revivicor, Revivicor, Blacksburg, VA, United States.

Kazuhiko Yamada (K)

Division of Transplantation, John Hopkins Medicine, Baltimore, MD, United States.

Daniel Eisenson (D)

Surgery, John Hopkins Medicine, Baltimore, MD, United States.

Muhammad Mohiuddin (M)

Surgery, University of Maryland Medical Center, Baltimore, MD, United States.

Will Eyestone (W)

Revivicor, Revivicor, Blacksburg, VA, United States.

J Craig Venter (JC)

J Craig Venter Institute, J Craig Venter Institute, Rockville, MD, United States.

Ryszard T Smolenski (RT)

Biochemistry, Medical University of Gdansk, Gdańsk, Poland.

Martine Rothblatt (M)

CEO Administration, United Therapeutics, Silver Spring, MD, United States.

Classifications MeSH